Review: Application of Nanoparticles in Urothelial Cancer of the Urinary Bladder

Overview

Journal J Med Biol Eng

Specialty Biomedical Engineering

Date 2015 Sep 5

PMID 26339222

Citations 7

Authors

Chieh-Hsiao Chen

Tzu-Min Chan

Yi-Jhen Wu

Jia-Jin Chen

Affiliations

Soon will be listed here.

Abstract

Bladder cancer is a common malignancy of the urinary tract, which generally develops in the epithelial lining of the urinary bladder. The specific course of treatment depends on the stage of bladder cancer; however, therapeutic strategies typically involve intravesical drug delivery to reduce toxicity and increase therapeutic effects. Recently, metallic, polymeric, lipid, and protein nanoparticles have been introduced to aid in the treatment of bladder cancer. Nanoparticles are also commonly used as pharmaceutical carriers to improve interactions between drugs and the urothelium. In this review, we classify the characteristics of bladder cancer and discuss the types of nanoparticles used in various treatment modalities. Finally we summarize the potential applications and benefits of various nanoparticles in intravesical therapy.

Citing Articles

Nanomedicine in Bladder Cancer Therapy.

Winnicka A, Brzeszczynska J, Saluk J, Wigner-Jeziorska P Int J Mol Sci. 2024; 25(19).

PMID: 39408718 PMC: 11476791. DOI: 10.3390/ijms251910388.

Unveiling FDA-approved Drugs and Formulations in the Management of Bladder Cancer: A Review.

Bansal K, Chaudhary N, Bhati H, Singh V Curr Pharm Biotechnol. 2024; 26(1):48-62.

PMID: 38797905 DOI: 10.2174/0113892010314650240514053735.

An Overview of siRNA Delivery Strategies for Urological Cancers.

Halib N, Pavan N, Trombetta C, Dapas B, Farra R, Scaggiante B Pharmaceutics. 2022; 14(4).

PMID: 35456552 PMC: 9030829. DOI: 10.3390/pharmaceutics14040718.

Nanotechnology in Bladder Cancer: Diagnosis and Treatment.

Barani M, Hosseinikhah S, Rahdar A, Farhoudi L, Arshad R, Cucchiarini M Cancers (Basel). 2021; 13(9).

PMID: 34063088 PMC: 8125468. DOI: 10.3390/cancers13092214.

Folic Acid-Doxorubicin-Double-Functionalized-Lipid-Core Nanocapsules: Synthesis, Chemical Structure Elucidation, and Cytotoxicity Evaluation on Ovarian (OVCAR-3) and Bladder (T24) Cancer Cell Lines.

Ce R, Lavayen V, Couto G, De Marchi J, Pacheco B, Natividade L Pharm Res. 2021; 38(2):301-317.

PMID: 33608808 DOI: 10.1007/s11095-021-02989-y.

References

Ehdaie B, Sylvester R, Herr H . Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol. 2013; 64(4):579-85. DOI: 10.1016/j.eururo.2013.05.027. View

Riaz M . Review article : stability and uses of liposomes. Pak J Pharm Sci. 1995; 8(2):69-79. View

Souto E, Wissing S, Barbosa C, Muller R . Comparative study between the viscoelastic behaviors of different lipid nanoparticle formulations. J Cosmet Sci. 2004; 55(5):463-71. View

Muir B, Acharya D, Kennedy D, Mulet X, Evans R, Pereira S . Metal-free and MRI visible theranostic lyotropic liquid crystal nitroxide-based nanoparticles. Biomaterials. 2012; 33(9):2723-33. DOI: 10.1016/j.biomaterials.2011.12.018. View

Anastasiadis A, de Reijke T . Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol. 2012; 4(1):13-32. PMC: 3263923. DOI: 10.1177/1756287211431976. View

Lu W, Arumugam S, Senapati D, Singh A, Arbneshi T, Khan S . Multifunctional oval-shaped gold-nanoparticle-based selective detection of breast cancer cells using simple colorimetric and highly sensitive two-photon scattering assay. ACS Nano. 2010; 4(3):1739-49. PMC: 2844490. DOI: 10.1021/nn901742q. View

Szlachcic A, Pala K, Zakrzewska M, Jakimowicz P, Wiedlocha A, Otlewski J . FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine. 2012; 7:5915-27. PMC: 3514973. DOI: 10.2147/IJN.S36575. View

Wehrung D, Oyewumi M . Antitumor effect of novel gallium compounds and efficacy of nanoparticle-mediated gallium delivery in lung cancer. J Biomed Nanotechnol. 2012; 8(1):161-71. DOI: 10.1166/jbn.2012.1361. View

Ando J, Yano T, Fujita K, Kawata S . Metal nanoparticles for nano-imaging and nano-analysis. Phys Chem Chem Phys. 2013; 15(33):13713-22. DOI: 10.1039/c3cp51806j. View

10.

Killion J, Fan D, Bucana C, Frangos D, Price J, Fidler I . Augmentation of antiproliferative activity of interferon alfa against human bladder tumor cell lines by encapsulation of interferon alfa within liposomes. J Natl Cancer Inst. 1989; 81(18):1387-92. DOI: 10.1093/jnci/81.18.1387. View

11.

Bailey A, Sullivan S . Efficient encapsulation of DNA plasmids in small neutral liposomes induced by ethanol and calcium. Biochim Biophys Acta. 2000; 1468(1-2):239-52. DOI: 10.1016/s0005-2736(00)00264-9. View

12.

Katoh T, Kaneko S, Takasawa S, Nagata N, Inatomi H, Ikemura K . Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. Pharmacogenetics. 1999; 9(2):165-9. View

13.

Porgador A, Gansbacher B, Bannerji R, Tzehoval E, Gilboa E, Feldman M . Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer. 1993; 53(3):471-7. DOI: 10.1002/ijc.2910530320. View

14.

Bohle A, Jocham D, Bock P . Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2002; 169(1):90-5. DOI: 10.1016/S0022-5347(05)64043-8. View

15.

Wu B, Cao X, Liang X, Zhang X, Zhang W, Sun G . Epigenetic regulation of Elf5 is associated with epithelial-mesenchymal transition in urothelial cancer. PLoS One. 2015; 10(1):e0117510. PMC: 4309403. DOI: 10.1371/journal.pone.0117510. View

16.

Patel S, Cohen A, Weiner A, Steinberg G . Intravesical therapy for bladder cancer. Expert Opin Pharmacother. 2015; 16(6):889-901. DOI: 10.1517/14656566.2015.1024656. View

17.

Villares G, Zigler M, Blehm K, Bogdan C, McConkey D, Colin D . Targeting EGFR in bladder cancer. World J Urol. 2007; 25(6):573-9. DOI: 10.1007/s00345-007-0202-7. View

18.

Aziz A, Shariat S, Roghmann F, Brookman-May S, Stief C, Rink M . Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making. BJU Int. 2014; 117(2):272-9. DOI: 10.1111/bju.12984. View

19.

Gardner J, Khurana H, Leach F, Ayala A, Zhai J, Ro J . Adenocarcinoma in ectopic prostatic tissue at dome of bladder: a case report of a patient with urothelial carcinoma of the bladder and adenocarcinoma of the prostate. Arch Pathol Lab Med. 2010; 134(9):1271-5. DOI: 10.5858/2009-0338-CR.1. View

20.

Nossier A, Eissa S, Ismail M, Hamdy M, Azzazy H . Direct detection of hyaluronidase in urine using cationic gold nanoparticles: a potential diagnostic test for bladder cancer. Biosens Bioelectron. 2013; 54:7-14. DOI: 10.1016/j.bios.2013.10.024. View